Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
2.050
-0.010 (-0.49%)
At close: Dec 5, 2025, 4:00 PM EST
2.040
-0.010 (-0.49%)
After-hours: Dec 5, 2025, 7:53 PM EST
Outlook Therapeutics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Outlook Therapeutics stock ranges from a low of $1.00 to a high of $9.00. The average analyst price target of $5.25 forecasts a 156.10% increase in the stock price over the next year.
Price Target: $5.25 (+156.10%)
Analyst Consensus: Buy
* Price targets were last updated on Sep 30, 2025.
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $1 | Hold | Reiterates | $1 | -51.22% | Sep 30, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $21 → $8 | Strong Buy | Maintains | $21 → $8 | +290.24% | Sep 22, 2025 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $1 | Strong Buy → Hold | Downgrades | $1 | -51.22% | Aug 29, 2025 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 | Hold | Maintains | $3 | +46.34% | Aug 28, 2025 |
Financial Forecast
Revenue This Year
6.86M
Revenue Next Year
30.38M
from 6.86M
Increased by 342.80%
EPS This Year
-1.68
from -4.06
EPS Next Year
-0.99
from -1.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 13.2M | 63.9M | ||||
| Avg | 6.9M | 30.4M | ||||
| Low | 4.1M | 15.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 831.8% | ||||
| Avg | - | 342.8% | ||||
| Low | - | 127.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.56 | -0.29 | ||||
| Avg | -1.68 | -0.99 | ||||
| Low | -1.78 | -1.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.